Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials
Jacob A. Udell(University Health Network), Deepak L. Bhatt(Mount Sinai Hospital), Marc S. Sabatine(Brigham and Women's Hospital), Marco Valgimigli(University of Bern), Cheol Whan Lee(Ulsan College), Francesco Costa(University of Messina), Jean‐Philippe Collet(Sorbonne Université), Laura Mauri(Brigham and Women's Hospital), Marc P. Bonaca(The Medical Center of Aurora), Seung‐Jung Park(Samsung Medical Center), A. Michael Lincoff(Cleveland Clinic), Eugene Braunwald(Mass General Brigham), Gilles Montalescot(Maastricht University Medical Centre)
Cited by 371
Related Papers
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k